Indication
H. pylori gastrointestinal tract infection
*H. Read more about H. pylori gastrointestinal tract infection
73 drugs 47 manufacturers
Drugs that treat it
Common H. pylori gastrointestinal tract infection therapies.
CLARITHROMYCIN
AMOXICILLIN
AMOXICILLIN
CLARITHROMYCIN
AMOXICILLIN
AMOXICILLIN
AMOXICILLIN
AMOXICILLIN
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soon*H.
pylori* gastrointestinal tract infection is a chronic bacterial colonization primarily affecting the gastric and proximal duodenal mucosa across pediatric and adult populations.
Caused by the flagellated, microaerophilic gram-negative bacterium *Helicobacter pylori*, the organism utilizes urease activity and virulence factors to neutralize gastric acid, penetrate the mucus layer, and adhere to epithelial cells.
This process triggers persistent mucosal inflammation and epithelial injury, frequently manifesting as asymptomatic or symptomatic chronic gastritis, dyspepsia, and peptic ulcer disease.
If untreated, the infection can progress along an inflammatory cascade leading to atrophic gastritis, intestinal metaplasia, gastric adenocarcinoma, or mucosa-associated lymphoid tissue (MALT) lymphoma.
- nih.gov
*H. pylori* gastrointestinal tract infection is a chronic bacterial colonization primarily affecting the gastric and proximal duodenal mucosa across pediatric and adult populations Caused by the flagellated, microaerophilic gram-negative bacterium *Helicobacter pylori*, the organism utilizes urease activity and virulence factors to neutralize gastric acid, penetrate the mucus layer, and adhere to epithelial cells This process triggers persistent mucosal inflammation and epithelial injury, freque...
- medlineplus.gov
*H. pylori* gastrointestinal tract infection is a chronic bacterial colonization primarily affecting the gastric and proximal duodenal mucosa across pediatric and adult populations
- nih.gov
Caused by the flagellated, microaerophilic gram-negative bacterium *Helicobacter pylori*, the organism utilizes urease activity and virulence factors to neutralize gastric acid, penetrate the mucus layer, and adhere to epithelial cells If untreated, the infection can progress along an inflammatory cascade leading to atrophic gastritis, intestinal metaplasia, gastric adenocarcinoma, or mucosa-associated lymphoid tissue (MALT) lymphoma
- fda.gov
Caused by the flagellated, microaerophilic gram-negative bacterium *Helicobacter pylori*, the organism utilizes urease activity and virulence factors to neutralize gastric acid, penetrate the mucus layer, and adhere to epithelial cells
- nih.gov
This process triggers persistent mucosal inflammation and epithelial injury, frequently manifesting as asymptomatic or symptomatic chronic gastritis, dyspepsia, and peptic ulcer disease
Personalize your experience
Follow H. pylori gastrointestinal tract infection and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.